Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Appili TherapeuticsAPLIF Revenue per Share is $0.00 as of Jun. 2026. The stock has 3 warning signs investors should review. Among 768 Biotechnology companies, Appili Therapeutics ranks worse than 70.05% on this metric.
Appili Therapeutics's revenue per share for the
three
months ended in Jun. 2026 was $0.00.
Appili Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.
Warning Sign:
Appili Therapeutics Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Appili Therapeutics was 200.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Appili Therapeutics's Revenue per Share or its related term are showing as below:
APLIF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -63.8 Med: -20.6 Max: -12.6
Current: -12.6
During the past 9 years, Appili Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was -12.60% per year. The lowest was -63.80% per year. And the median was -20.60% per year.
APLIF's 3-Year Revenue Growth Rate is ranked worse than 70.05% of 768
companies
in the Biotechnology industry
Industry Median: 3.1
vs APLIF: -12.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Appili Therapeutics Revenue per Share Related Terms
Appili Therapeutics Revenue per Share Historical Data
* Premium members only.
The historical data trend for Appili Therapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APLIF vs VRTX, REGN, MRNA: Revenue per Share Comparison
For the Biotechnology subindustry, Appili Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Appili Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Appili Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Appili Therapeutics's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Appili Therapeutics's Revenue Per Share for the fiscal year that ended in Mar. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Appili Therapeutics (APLIF) has a Revenue per Share of $0.00 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Appili Therapeutics and its competitors. According to the industry distribution chart, Appili Therapeutics ranks #538 out of 768 companies in the Biotechnology industry, placing it in the top 70.1%.
Is Appili Therapeutics' Revenue per Share too high?
Appili Therapeutics' current Revenue per Share is $0.00. Based on the distribution chart, Appili Therapeutics ranks #538 out of 768 companies in the Biotechnology industry, which is below the industry midpoint.
How does Appili Therapeutics' Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Appili Therapeutics ranks #538 out of 768 companies for Revenue per Share. This places Appili Therapeutics in the lower half of its industry. The industry median Revenue per Share is 3.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Appili Therapeutics and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Appili Therapeutics's current Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 64% below its estimated fair value. The current Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current Revenue per Share is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLIF has been successfully added to your 
